View as Webpage

The 114th Annual Meeting of the American Association for Cancer Research (AACR) was held April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. More 170+ reports and presentations in AACR Annual Meeting showcase the advanced progress in ADCs.

Selected presentation highlights:

•  AZD9592 is a first-in-class bispecific ADC designed to target EGFR x c-MET, conjugated to a topoisomerase-1 inhibitor (TOP1i) using the AstraZeneca’s proprietary linker technology. Data shows a promising efficacy and safety profile in preclinical models, with evidence for DNA damage dependent tumour cell death as the mechanism of action.
•  AZD5335 was designed using, an ADC targeting folate receptor alpha (FRα), anti-FRα antibody linked to a proprietary TOP1i warhead. A robust anti-tumour response is reported in FRα-expressing preclinical models that are resistant to another FRα ADC with a microtubule inhibitor warhead.
• ZW191, a novel FRα-targeting ADC bearing a TOP1i payload. According to data, ZW191 exhibited a compelling preclinical activity profile that supports potential activity in targeting FRα-high/mid/low ovarian cancers.

ADC target proteins from ACROBiosystems (partial)

Proteases for peptide linker

AGLink™ ADC site-specific conjugation kits

Tools for ADCs PK analysis

To receive the latest industry news and updates from ACROBiosystems,

visit our website & follow us on our social media!